Study of CA-008 (Vocacapsaicin) in Bunionectomy Patients

• Status: Completed
• Trial end date: 2018-10-23
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled, parallel design study evaluating a single dose of one of three CA-008 dose levels vs. placebo injected during an elective bunionectomy Bunionectomy to assess post-surgical pain management and the need for rescue medication (oxycodone).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Concentric Analgesics
• Treatments: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Bupivacaine; Ketorolac; Oxycodone

Criteria

Inclusion Criteria:

1. Healthy adult aged 18 - 75 years old

2. American Society of Anesthesiology (ASA) physical Class 1, 2 or 3

3. Planning elective Bunionectomy repair

4. For both males and females: using an acceptable method of birth control

5. If a female: not pregnant or breastfeeding

6. Have a body mass index ≤ 40 kg/m2.

7. Be willing and able to sign the informed consent form (ICF)

8. Be able to complete study procedures and pain scales and to communicate meaningfully in English

9. Be willing to undergo 17 blood draws for pharmacokinetic (PK )assessments over 24 hours

Exclusion Criteria:

1. Have another painful condition, other than bunion-related pain, that may require pain treatment during the study period

2. Have active skin disease or another abnormality at the anticipated site of surgery that could interfere with the planned surgery.

3. Have a known allergy to chili peppers, capsaicin or the components of CA-008, bupivacaine HCl, ketorolac, acetaminophen or oxycodone.

4. Have a history of significant medical, neuropsychiatric or other condition, including a clinically significant abnormal clinical laboratory test values

5. Be on any medication not allowed per the protocol

6. Within the past year have a history of illicit drug use or prescription medicine or alcohol abuse

7. Have positive results on the alcohol test (breath or saliva) or urine drug screen

8. Have previously participated in a clinical study with CA-008.

9. Have participated in another clinical trial or used an investigational product within 30 days or five half-lives (whichever is longer)